-$0.40 Earnings Per Share Expected for Corvus Pharmaceuticals Inc (CRVS) This Quarter
Wall Street brokerages expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to post ($0.40) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Corvus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.39). Corvus Pharmaceuticals posted earnings per share of ($0.58) in the same quarter last year, which would indicate a positive year-over-year growth rate of 31%. The company is scheduled to announce its next earnings results on Thursday, March 7th.
On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($1.81) to ($1.74). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.59) per share, with EPS estimates ranging from ($1.65) to ($1.52). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, November 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.12.
Shares of NASDAQ CRVS traded up $0.08 during mid-day trading on Monday, reaching $4.12. 51,754 shares of the company’s stock were exchanged, compared to its average volume of 151,822. The firm has a market cap of $118.30 million, a P/E ratio of -1.51 and a beta of 0.90. Corvus Pharmaceuticals has a twelve month low of $3.22 and a twelve month high of $13.91.
In other news, CEO Richard A. Md Miller bought 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 27th. The shares were acquired at an average price of $3.29 per share, with a total value of $65,800.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Richard A. Md Miller bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, December 20th. The stock was purchased at an average cost of $4.40 per share, for a total transaction of $44,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 81,202 shares of company stock worth $316,992. 39.50% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in CRVS. BlackRock Inc. raised its position in Corvus Pharmaceuticals by 51.9% in the 2nd quarter. BlackRock Inc. now owns 1,119,507 shares of the company’s stock valued at $12,290,000 after buying an additional 382,389 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Corvus Pharmaceuticals by 66.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 260,701 shares of the company’s stock valued at $2,237,000 after buying an additional 104,230 shares during the last quarter. Renaissance Technologies LLC raised its position in Corvus Pharmaceuticals by 22.2% in the 3rd quarter. Renaissance Technologies LLC now owns 396,900 shares of the company’s stock valued at $3,405,000 after buying an additional 72,000 shares during the last quarter. Northern Trust Corp increased its position in shares of Corvus Pharmaceuticals by 69.2% during the 2nd quarter. Northern Trust Corp now owns 149,846 shares of the company’s stock worth $1,645,000 after purchasing an additional 61,276 shares during the last quarter. Finally, Hikari Power Ltd acquired a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $275,000. 87.42% of the stock is currently owned by institutional investors and hedge funds.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Story: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.